These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24225331)

  • 61. Transmissibility of human myelomatosis.
    Chang TC
    Lancet; 1972 Jan; 1(7741):94. PubMed ID: 4108968
    [No Abstract]   [Full Text] [Related]  

  • 62. [Molecular biology of multiple myeloma: introduction].
    Nihon Rinsho; 2016 Jul; 74 Suppl 5():87-91. PubMed ID: 30615312
    [No Abstract]   [Full Text] [Related]  

  • 63. Hyperhaploid karyotypes in multiple myeloma.
    Sawyer JR; Morgan GJ
    Oncotarget; 2017 Oct; 8(45):78259-78260. PubMed ID: 29108224
    [No Abstract]   [Full Text] [Related]  

  • 64. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
    Vincent Rajkumar S
    Am J Hematol; 2014 Oct; 89(10):999-1009. PubMed ID: 25223428
    [TBL] [Abstract][Full Text] [Related]  

  • 65. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
    Rajkumar SV; Dimopoulos MA; Palumbo A; Blade J; Merlini G; Mateos MV; Kumar S; Hillengass J; Kastritis E; Richardson P; Landgren O; Paiva B; Dispenzieri A; Weiss B; LeLeu X; Zweegman S; Lonial S; Rosinol L; Zamagni E; Jagannath S; Sezer O; Kristinsson SY; Caers J; Usmani SZ; Lahuerta JJ; Johnsen HE; Beksac M; Cavo M; Goldschmidt H; Terpos E; Kyle RA; Anderson KC; Durie BG; Miguel JF
    Lancet Oncol; 2014 Nov; 15(12):e538-48. PubMed ID: 25439696
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice.
    Landgren O; Morgan GJ
    Clin Cancer Res; 2014 Feb; 20(4):804-13. PubMed ID: 24270684
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma.
    Shin SY; Lee ST; Kim HJ; Kim SJ; Kim K; Kang ES; Kim SH
    J Clin Lab Anal; 2015 Nov; 29(6):505-10. PubMed ID: 25277787
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Myeloma genetics and genomics: practice implications and future directions.
    Faiman B
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):436-40. PubMed ID: 25127058
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma.
    Bianchi G; Ghobrial IM
    Curr Cancer Ther Rev; 2014; 10(2):70-79. PubMed ID: 25705146
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Multiple myeloma: a model for scientific and clinical progress.
    San Miguel J
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):1-7. PubMed ID: 25696828
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience.
    Hebraud B; Magrangeas F; Cleynen A; Lauwers-Cances V; Chretien ML; Hulin C; Leleu X; Yon E; Marit G; Karlin L; Roussel M; Stoppa AM; Belhadj K; Voillat L; Garderet L; Macro M; Caillot D; Mohty M; Facon T; Moreau P; Attal M; Munshi N; Corre J; Minvielle S; Avet-Loiseau H
    Blood; 2015 Mar; 125(13):2095-100. PubMed ID: 25636340
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Risk stratification in multiple myeloma, part 1: characterization of high-risk disease.
    Biran N; Jagannath S; Chari A
    Clin Adv Hematol Oncol; 2013 Aug; 11(8):489-503. PubMed ID: 24518420
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.
    Bolli N; Avet-Loiseau H; Wedge DC; Van Loo P; Alexandrov LB; Martincorena I; Dawson KJ; Iorio F; Nik-Zainal S; Bignell GR; Hinton JW; Li Y; Tubio JM; McLaren S; O' Meara S; Butler AP; Teague JW; Mudie L; Anderson E; Rashid N; Tai YT; Shammas MA; Sperling AS; Fulciniti M; Richardson PG; Parmigiani G; Magrangeas F; Minvielle S; Moreau P; Attal M; Facon T; Futreal PA; Anderson KC; Campbell PJ; Munshi NC
    Nat Commun; 2014; 5():2997. PubMed ID: 24429703
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cytogenetic classification in Korean multiple myeloma patients: prognostic significance of hyperdiploidy with 47-50 chromosomes and the number of structural abnormalities.
    Lim JH; Seo EJ; Park CJ; Jang S; Chi HS; Suh C; Kim H; Kim SR
    Eur J Haematol; 2014 Apr; 92(4):313-20. PubMed ID: 24372944
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.
    Abdi J; Chen G; Chang H
    Oncotarget; 2013 Dec; 4(12):2186-207. PubMed ID: 24327604
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.
    Langer P; John L; Monsef I; Scheid C; Piechotta V; Skoetz N
    Cochrane Database Syst Rev; 2024 May; 5(5):CD013595. PubMed ID: 38695605
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Predicting cytogenetic risk in multiple myeloma using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI, and spinal diffusion-weighted imaging.
    Van Den Berghe T; Verberckmoes B; Kint N; Wallaert S; De Vos N; Algoet C; Behaeghe M; Dutoit J; Van Roy N; Vlummens P; Dendooven A; Van Dorpe J; Offner F; Verstraete K
    Insights Imaging; 2024 Apr; 15(1):106. PubMed ID: 38597979
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Variability of definition of high-risk multiple myeloma across phase III clinical trials.
    Abu Za'nouneh FJ; Ababneh O; Schinke C; Thanendrarajan S; Zangari M; Shaughnessy JD; Zhan F; van Rhee F; Al Hadidi S
    EJHaem; 2023 May; 4(2):454-458. PubMed ID: 37206288
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK.
    Salimi A; Schroeder KM; Schemionek-Reinders M; Vieri M; Maletzke S; Gezer D; Masouleh BK; Appelmann I
    BMC Cancer; 2022 Jul; 22(1):735. PubMed ID: 35790913
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prediction and prognostic significance of BCAR3 expression in patients with multiple myeloma.
    Zhang W; Lin Y; Liu X; He X; Zhang Y; Fu W; Yang Z; Yang P; Wang J; Hu K; Zhang X; Liu W; Yuan X; Jing H
    J Transl Med; 2018 Dec; 16(1):363. PubMed ID: 30563570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.